|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 111 K Street, NE |
Address2 | Ninth Floor |
City | Washington |
State | DC |
Zip Code | 20002 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 401105339-12
|
||||||||
|
6. House ID# 444750001
|
TYPE OF REPORT | 8. Year | 2024 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Mark L. Hayes |
Date | 4/19/2024 5:42:43 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
340B Program; Issues related to affordable prescription drugs; Issues related to health care workforce and staffing; Issues related to health care privacy; Issues related to telehealth authorities; Issues related to hospital price transparency; Issues related to hospital reimbursement; Issues related to nonprofit hospital practices; Issues related to hospital outpatient department payments; Issues related to hospital outpatient department payments; Medicaid Disproportionate Share Hospital payment adjustment program; Issues related to Medicare payments; Issues related to Medicare Advantage payment and prior authorization Childrens Hospital Graduate Medical Education Program (CHGME); issues related to childrens medical care; Future Advancement of Academic Nursing (FAAN) Act; Veteran Nurses in Primary Care Program; H.R. 2584/S. 2768, the Safety From Violence for Healthcare Employees (SAVE) Act; Expanding Care in the Home Act; H.R. 1770, Equitable Access to Pharmacy Services Act; issues related to Program for All-Inclusive Care for the Elderly (PACE); H.R. 1770, Equitable Access to Pharmacy Services Act; H.R. 3008, the Drug Shortage Prevention Act; H.R. 3810, the Drug Origin Transparency Act; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act; issues related to preventing and mitigating drug shortages; H.R. 2389/S. 1302, the Resident Physician Shortage Reduction Act; H.R. 3263, the Support Faculty and Expand Access to Nursing Act; issues related to prior authorization, unwarranted claim denials, and payment delays; S. 2840, the Bipartisan Primary Care and Health Workforce Expansion Act; H.R. 3561, the PATIENT Act; H.R. 6363, Further Continuing Appropriations and Other Extension Act; H.R. 5378, the Lower Costs, More Transparency Act; Issues related to mental and behavioral health; the limit on Medicare payment days for inpatient psychiatric care; the Institutions for Mental Disease exclusion; issues related to extending programs under the SUPPORT for Patients Communities Act.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Peter |
Leibold |
|
|
|
Mark |
Hayes |
|
2004-2010:Health Policy Director & 2002-2004:Health Policy Advisor, Sen Finance Cmte; 2001-2002: Sr Health Policy Advsr, Sen. Snowe; 2001:Health Policy Advsr, Sen HELP Cmte; 94-95:Sr Advisor, Sen Sm Bus. Cmte; 94-99:LA 89-90:Staff Asst, Sen. Bond |
|
Joseph |
Lustig |
|
2019-2020: Senior Policy Advisor, 2017-2019: Policy Advisor, 2015-2017: Legislative Assistant, 2014-2015: Legislative Correspondent, 2014: Staff Assistant, Rep. Cedric L. Richmond |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Issues related to affordable prescription drugs; Issues related to telehealth authorities; Issues related to health care workforce and staffing; Medicaid Disproportionate Share Hospital payment adjustment program; Issues related to Medicaid coverage; Issues related to hospital reimbursement; 340B Program; Issues related to hospital price transparency; Issues related to Medicare payments; Issues related to Medicare Advantage payment and prior authorization; Future Advancement of Academic Nursing (FAAN) Act; Expanding Care in the Home Act; H.R. 1770, Equitable Access to Pharmacy Services Act; issues related to Program for All-Inclusive Care for the Elderly (PACE); issues related to improving coordination of care for dual eligibles; issues related to site neutral payments; H.R. 3281, the Transparent PRICE Act; issues related to prior authorization, unwarranted claim denials, and payment delays; the Biologics Price Competition and Innovation Act (BPCIA); H.R. 3561, the PATIENT Act; H.R. 6363, Further Continuing Appropriations and Other Extension Act; H.R. 5378, the Lower Costs, More Transparency Act; PL 118-42/H.R. 4366 - Consolidated Appropriations Act, 2024; PL 118-47/H.R. 2882 - Consolidated Appropriations Act, 2024; Issues related to mental and behavioral health; the limit on Medicare payment days for inpatient psychiatric care; the Institutions for Mental Disease exclusion; issues related to extending programs under the SUPPORT for Patients Communities Act.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Peter |
Leibold |
|
|
|
Mark |
Hayes |
|
2004-2010:Health Policy Director & 2002-2004:Health Policy Advisor, Sen Finance Cmte; 2001-2002: Sr Health Policy Advsr, Sen. Snowe; 2001:Health Policy Advsr, Sen HELP Cmte; 94-95:Sr Advisor, Sen Sm Bus. Cmte; 94-99:LA 89-90:Staff Asst, Sen. Bond |
|
Joseph |
Lustig |
|
2019-2020: Senior Policy Advisor, 2017-2019: Policy Advisor, 2015-2017: Legislative Assistant, 2014-2015: Legislative Correspondent, 2014: Staff Assistant, Rep. Cedric L. Richmond |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
340B Program; Issues related to affordable prescription drugs;H.R. 1770, Equitable Access to Pharmacy Services Act; H.R. 3008, the Drug Shortage Prevention Act; H.R. 3810, the Drug Origin Transparency Act; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act; issues related to preventing and mitigating drug shortages;
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Health Resources & Services Administration (HRSA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Peter |
Leibold |
|
|
|
Mark |
Hayes |
|
2004-2010:Health Policy Director & 2002-2004:Health Policy Advisor, Sen Finance Cmte; 2001-2002: Sr Health Policy Advsr, Sen. Snowe; 2001:Health Policy Advsr, Sen HELP Cmte; 94-95:Sr Advisor, Sen Sm Bus. Cmte; 94-99:LA 89-90:Staff Asst, Sen. Bond |
|
Joseph |
Lustig |
|
2019-2020: Senior Policy Advisor, 2017-2019: Policy Advisor, 2015-2017: Legislative Assistant, 2014-2015: Legislative Correspondent, 2014: Staff Assistant, Rep. Cedric L. Richmond |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |